drugset / Trial / NCT00350415
A Double Blind Study for the Treatment of Acute Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).
Timeline
- Start
- 2006-06
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesalamine | Small molecule | 400 mg | Oral |
| Subject | Mesalamine | Small molecule | 800 mg | Oral |